AU4255397A – Chimpanzee adenovirus vectors
– Google Patents
AU4255397A – Chimpanzee adenovirus vectors
– Google Patents
Chimpanzee adenovirus vectors
Info
Publication number
AU4255397A
AU4255397A
AU42553/97A
AU4255397A
AU4255397A
AU 4255397 A
AU4255397 A
AU 4255397A
AU 42553/97 A
AU42553/97 A
AU 42553/97A
AU 4255397 A
AU4255397 A
AU 4255397A
AU 4255397 A
AU4255397 A
AU 4255397A
Authority
AU
Australia
Prior art keywords
adenovirus vectors
chimpanzee adenovirus
chimpanzee
vectors
adenovirus
Prior art date
1996-09-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU42553/97A
Inventor
Steven F. Farina
Krishna J Fisher
James M. Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1996-09-06
Filing date
1997-09-04
Publication date
1998-03-26
1997-09-04
Application filed by University of Pennsylvania Penn
filed
Critical
University of Pennsylvania Penn
1998-03-26
Publication of AU4255397A
publication
Critical
patent/AU4255397A/en
Status
Abandoned
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
Classifications
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
C12N15/09—Recombinant DNA-technology
C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
C12N15/86—Viral vectors
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K38/00—Medicinal preparations containing peptides
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
C12N2710/00011—Details
C12N2710/10011—Adenoviridae
C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
C12N2710/00011—Details
C12N2710/10011—Adenoviridae
C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
C12N2710/00011—Details
C12N2710/10011—Adenoviridae
C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
C12N2710/10341—Use of virus, viral particle or viral elements as a vector
C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
C12N2710/00011—Details
C12N2710/10011—Adenoviridae
C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
C12N2710/10341—Use of virus, viral particle or viral elements as a vector
C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N2830/00—Vector systems having a special element relevant for transcription
C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N2840/00—Vectors comprising a special translation-regulating system
C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
AU42553/97A
1996-09-06
1997-09-04
Chimpanzee adenovirus vectors
Abandoned
AU4255397A
(en)
Applications Claiming Priority (3)
Application Number
Priority Date
Filing Date
Title
US2470096P
1996-09-06
1996-09-06
US60024700
1996-09-06
PCT/US1997/015694
WO1998010087A1
(en)
1996-09-06
1997-09-04
Chimpanzee adenovirus vectors
Publications (1)
Publication Number
Publication Date
AU4255397A
true
AU4255397A
(en)
1998-03-26
Family
ID=21821939
Family Applications (1)
Application Number
Title
Priority Date
Filing Date
AU42553/97A
Abandoned
AU4255397A
(en)
1996-09-06
1997-09-04
Chimpanzee adenovirus vectors
Country Status (3)
Country
Link
US
(1)
US6083716A
(en)
AU
(1)
AU4255397A
(en)
WO
(1)
WO1998010087A1
(en)
Families Citing this family (142)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US6492343B1
(en)
*
1998-04-15
2002-12-10
University Of Saskatchewan
Porcine adenovirus type 3 genome
DE10056210A1
(en)
*
2000-11-13
2002-05-29
Arimedes Biotechnology Gmbh
Viral expression system
CA2451864C
(en)
*
2001-06-22
2013-01-15
The Wistar Institute Of Anatomy And Biology
Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
JP4399255B2
(en)
*
2001-06-22
2010-01-13
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア
A method for rapid selection of bacterial transformants and a novel simian adenovirus protein
US20040136963A1
(en)
*
2001-06-22
2004-07-15
The Trustees Of The University Of Pennsylvania
Simian adenovirus vectors and methods of use
CN102181480B
(en)
2001-11-13
2016-01-27
宾夕法尼亚大学托管会
Detect and/or identify the method for the novel sequences that adeno associated virus (AAV) sequence and separation are identified
AU2007201747B2
(en)
*
2001-11-21
2010-06-03
The Trustees Of The University Of Pennsylvania
Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
EP1944043A1
(en)
2001-11-21
2008-07-16
The Trustees of the University of Pennsylvania
Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
SG165153A1
(en)
2001-11-21
2010-10-28
Univ Pennsylvania
Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
CA2479118A1
(en)
*
2002-03-15
2003-09-25
Wyeth Holdings Corporation
Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
AU2003285932A1
(en)
2002-10-23
2004-05-13
Glaxosmithkline Biologicals S.A.
Methods for vaccinating against malaria
ES2478625T3
(en)
*
2003-06-20
2014-07-22
The Trustees Of The University Of Pennsylvania
Method of generating chimeric adenoviruses and uses of such chimeric adenoviruses
US7291498B2
(en)
2003-06-20
2007-11-06
The Trustees Of The University Of Pennsylvania
Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
US20050036989A1
(en)
*
2003-07-18
2005-02-17
Onyx Pharmaceuticals, Inc.
Subgroup B adenoviral vectors for treating disease
WO2005012537A2
(en)
*
2003-07-25
2005-02-10
Genvec, Inc.
Adenoviral vector-based vaccines
US7687613B2
(en)
*
2003-08-27
2010-03-30
Cornell Research Foundation, Inc.
Genetic vaccines directed against bacterial exotoxins
WO2005063970A1
(en)
*
2003-12-23
2005-07-14
Schering Corporation
Methods for producing a549 cell lines stable in serum-free medium suspension culture
CA3028774A1
(en)
*
2004-01-23
2005-08-04
Msd Italia S.R.L.
Chimpanzee adenovirus vaccine carriers
JP2007535550A
(en)
*
2004-04-28
2007-12-06
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア
Continuous delivery of immunogenic molecules via adenovirus and adeno-associated virus mediated administration
CA2563500C
(en)
*
2004-04-28
2016-06-28
The Trustees Of The University Of Pennsylvania
Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost
GB0417494D0
(en)
2004-08-05
2004-09-08
Glaxosmithkline Biolog Sa
Vaccine
EP1784493A2
(en)
*
2004-09-01
2007-05-16
The Government of the United States of America as Represented by The Department of Health and Human Services
Adenoviral vectors able to transduce apcs, potential use in immune response generation
MX2007005256A
(en)
2004-11-16
2008-03-11
Crucell Holland Bv
Multivalent vaccines comprising recombinant viral vectors.
AR053275A1
(en)
*
2005-05-12
2007-04-25
Glaxo Group Ltd
VACCINE COMPOSITION
GB0513421D0
(en)
2005-06-30
2005-08-03
Glaxosmithkline Biolog Sa
Vaccines
US20090074810A1
(en)
*
2006-04-28
2009-03-19
The Trustees Of The University Of Pennsylvania
Modified Adenovirus Hexon Protein and Uses Thereof
EP2040742B1
(en)
2006-07-18
2014-10-29
GlaxoSmithKline Biologicals S.A.
Vaccines for malaria
JP5869206B2
(en)
2007-03-02
2016-02-24
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Novel methods and compositions
AU2008288508B2
(en)
2007-08-13
2014-05-01
Glaxosmithkline Biologicals S.A.
Vaccines
AU2014203073B2
(en)
*
2007-11-28
2016-07-07
The Trustees Of The University Of Pennsylvania
Simian E adenovirus SAdV-30
EP2220217A2
(en)
2007-11-28
2010-08-25
The Trustees of the University of Pennsylvania
Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof
ES2621165T3
(en)
*
2007-11-28
2017-07-03
The Trustees Of The University Of Pennsylvania
Ape adenovirus of subfamily B SADV-28, -27, -29, -32, -33 and -35 and uses thereof
CN101883858B
(en)
2007-11-28
2015-07-22
宾夕法尼亚大学托管会
Simian subfamily E adenoviruses SAdV-39, -25.2, -26, -30, -37, and -38 and uses thereof
US20090202492A1
(en)
*
2008-01-25
2009-08-13
University Of South Florida
Adenovirus vaccine utilizing ikk as adjuvant
CA2716928C
(en)
2008-03-04
2018-04-10
The Trustees Of The University Of Pennsylvania
Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
US9217155B2
(en)
*
2008-05-28
2015-12-22
University Of Massachusetts
Isolation of novel AAV’S and uses thereof
ES2552688T3
(en)
*
2008-10-31
2015-12-01
The Trustees Of The University Of Pennsylvania
Ape adenovirus with SAdV-46 hexon capsid proteins and uses thereof
CN102575284A
(en)
2009-03-17
2012-07-11
MDx健康公司
Improved detection of gene expression
WO2010138263A2
(en)
2009-05-28
2010-12-02
University Of Massachusetts
Novel aav ‘s and uses thereof
US8846031B2
(en)
2009-05-29
2014-09-30
The Trustees Of The University Of Pennsylvania
Simian adenovirus 41 and uses thereof
JP5903045B2
(en)
*
2009-07-31
2016-04-13
パックスバックス， インコーポレイテッド
Adenovirus based vector
WO2011057254A2
(en)
2009-11-09
2011-05-12
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Simian adenoviral vector-based vaccines
WO2011057248A2
(en)
2009-11-09
2011-05-12
Genvec, Inc.
Simian adenovirus and methods of use
US9526777B2
(en)
2010-04-16
2016-12-27
The United States Of America As Represented By The Department Of Health And Human Services
Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein
US9272053B2
(en)
2010-04-23
2016-03-01
University Of Massachusetts
AAV-based treatment of cholesterol-related disorders
EP3536781A1
(en)
2010-04-23
2019-09-11
University of Massachusetts
Cns targeting aav vectors and methods of use thereof
WO2011133874A1
(en)
2010-04-23
2011-10-27
University Of Massachusetts
Multicistronic expression constructs
AP3390A
(en)
2010-09-20
2015-08-31
Crucell Holland Bv
Therapeutic vaccination against active tuberculosis
WO2012071318A2
(en)
2010-11-23
2012-05-31
The Trustees Of The University Of Pennsylvania
Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof
WO2012088608A1
(en)
2010-12-27
2012-07-05
Enobia Canada Limited Partnership
Compositions comprising natriuretic peptides and methods of use thereof
SG11201401605QA
(en)
2011-10-19
2014-09-26
Alexion Pharma Holding
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9226936B2
(en)
2011-10-28
2016-01-05
The Wistar of Anatomy and Biology
Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
EP2780034A1
(en)
2011-11-14
2014-09-24
Crucell Holland B.V.
Heterologous prime-boost immunization using measles virus-based vaccines
US10238755B2
(en)
2011-11-30
2019-03-26
The Wistar Institute Of Anatomy And Biology
Methods and compositions for regulation of cell aging, carcinogenesis and reprogramming
EP2825640B1
(en)
2012-03-12
2016-04-27
Crucell Holland B.V.
Batches of recombinant adenovirus with altered terminal ends
US8932607B2
(en)
2012-03-12
2015-01-13
Crucell Holland B.V.
Batches of recombinant adenovirus with altered terminal ends
MX358019B
(en)
2012-05-18
2018-08-02
Univ Pennsylvania
Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof.
EP2892554B1
(en)
2012-09-07
2020-08-26
Emory University
Hiv immune stimulating compositions comprising recombinantly expressed pili on bacteria and methods related thereto
US9402888B2
(en)
2013-03-14
2016-08-02
The Wistar Institute Of Anatomy And Biology
Methods and compositions for treating cancer
KR102236497B1
(en)
2013-04-25
2021-04-06
얀센 백신스 앤드 프리벤션 비.브이.
Stabilized soluble prefusion rsv f polypeptides
CN105682679B
(en)
2013-11-01
2020-12-08
辉瑞公司
Vectors for expression of prostate-associated antigens
EP3134522B1
(en)
2014-04-25
2021-10-06
University of Massachusetts
Recombinant aav vectors useful for reducing immunity against transgene products
EP3151866B1
(en)
2014-06-09
2023-03-08
Voyager Therapeutics, Inc.
Chimeric capsids
US11571472B2
(en)
2014-06-13
2023-02-07
Glaxosmithkline Biologicals Sa
Immunogenic combinations
SG11201701745TA
(en)
2014-09-03
2017-04-27
Bavarian Nordic As
Methods and compositions for enhancing immune responses
NZ730511A
(en)
2014-09-03
2022-04-29
Janssen Vaccines & Prevention Bv
Methods and compositions for inducing protective immunity against filovirus infection
AP2017009846A0
(en)
2014-09-26
2017-03-31
Beth Israel Deaconess Medical Ct Inc
Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
JP6842410B2
(en)
2014-10-03
2021-03-17
ユニバーシティ オブ マサチューセッツ
AAV vector identified by a novel high efficiency library
US10941452B2
(en)
2014-10-06
2021-03-09
The Trustees Of The University Of Pennsylvania
Compositions and methods for isolation of circulating tumor cells (CTC)
CN107073051B
(en)
2014-10-21
2021-08-24
马萨诸塞大学
Recombinant AAV variants and uses thereof
EP3215191A4
(en)
2014-11-05
2018-08-01
Voyager Therapeutics, Inc.
Aadc polynucleotides for the treatment of parkinson’s disease
CA2975583A1
(en)
2014-11-14
2016-05-19
Voyager Therapeutics, Inc.
Modulatory polynucleotides
CA2967367C
(en)
2014-11-14
2023-05-16
Voyager Therapeutics, Inc.
Compositions and methods of treating amyotrophic lateral sclerosis (als)
EP3230441A4
(en)
2014-12-12
2018-10-03
Voyager Therapeutics, Inc.
Compositions and methods for the production of scaav
PL3283634T3
(en)
2015-04-14
2019-10-31
Janssen Vaccines & Prevention Bv
Recombinant adenovirus expressing two transgenes with a bidirectional promoter
EP3285788A4
(en)
2015-04-23
2018-12-05
University of Massachusetts
Modulation of aav vector transgene expression
JP7189014B2
(en)
2015-07-07
2022-12-13
ヤンセン ファッシンズ アンド プリベンション ベーフェー
Vaccine against RSV
CA2991540A1
(en)
2015-07-07
2017-01-12
Janssen Vaccines & Prevention B.V.
Stabilized soluble pre-fusion respiratory syncytial sirus polypeptides
WO2017096162A1
(en)
2015-12-02
2017-06-08
Voyager Therapeutics, Inc.
Assays for the detection of aav neutralizing antibodies
WO2017102929A1
(en)
2015-12-15
2017-06-22
Janssen Vaccines & Prevention B.V.
Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
WO2017142988A1
(en)
2016-02-18
2017-08-24
The Wistar Institute Of Anatomy And Biology
Methods and compositions for treating melanoma
IL291604B1
(en)
2016-04-05
2023-10-01
Janssen Vaccines Prevention B V
Stabilized soluble pre-fusion rsv f proteins
MA43762A
(en)
2016-04-05
2021-04-21
Janssen Vaccines & Prevention Bv
VACCINE AGAINST RSV
WO2017189964A2
(en)
2016-04-29
2017-11-02
Voyager Therapeutics, Inc.
Compositions for the treatment of disease
US11326182B2
(en)
2016-04-29
2022-05-10
Voyager Therapeutics, Inc.
Compositions for the treatment of disease
ES2829272T3
(en)
2016-05-12
2021-05-31
Janssen Vaccines & Prevention Bv
Powerful and balanced bidirectional promoter
BR112018073384A2
(en)
2016-05-18
2019-03-06
Voyager Therapeutics, Inc.
modulating polynucleotides
CA3025441A1
(en)
2016-05-30
2017-12-07
Janssen Vaccines & Prevention B.V.
Stabilized pre-fusion rsv f proteins
JP6683847B2
(en)
2016-06-20
2020-04-22
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ．
Strong and balanced bidirectional promoter
WO2018011198A1
(en)
2016-07-15
2018-01-18
Janssen Vaccines & Prevention B.V.
Methods and compositions for inducing protective immunity against a marburg virus infection
EP3484507A1
(en)
2016-07-15
2019-05-22
Janssen Vaccines & Prevention B.V.
Methods and compositions for inducing protective immunity against a marburg virus infection
KR20190055086A
(en)
2016-08-19
2019-05-22
칼리뮨, 인코포레이티드
Methods and compositions for treating conditions using recombinant self-complementary adeno-associated viruses
EP3831281A1
(en)
2016-08-30
2021-06-09
The Regents of The University of California
Methods for biomedical targeting and delivery and devices and systems for practicing the same
WO2018060288A1
(en)
2016-09-29
2018-04-05
Glaxosmithkline Biologicals S.A.
Compositions and methods of treatment of persistent hpv infection
KR20190075964A
(en)
2016-10-13
2019-07-01
유니버시티 오브 매사추세츠
AAV capsid design
PE20191345A1
(en)
2016-11-23
2019-09-30
Gritstone Oncology Inc
VIRAL ADMINISTRATION OF NEOANTIGENS
GB201620968D0
(en)
2016-12-09
2017-01-25
Glaxosmithkline Biologicals Sa
Adenovirus polynucleotides and polypeptides
EP3562498A4
(en)
2016-12-28
2020-10-28
Invvax, Inc.
Influenza vaccines
CN110268061A
(en)
2017-02-09
2019-09-20
扬森疫苗与预防公司
For expressing the effective short promoter of heterologous gene
WO2018185732A1
(en)
2017-04-06
2018-10-11
Janssen Vaccines & Prevention B.V.
Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
CA3061368A1
(en)
2017-05-05
2018-11-08
Voyager Therapeutics, Inc.
Compositions and methods of treating huntington’s disease
WO2018204786A1
(en)
2017-05-05
2018-11-08
Voyager Therapeutics, Inc.
Compositions and methods of treating amyotrophic lateral sclerosis (als)
TW201907937A
(en)
2017-05-08
2019-03-01
美商葛利史東腫瘤科技公司
Alpha virus new antigen vector
JP2020519663A
(en)
2017-05-17
2020-07-02
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ．
Methods and compositions for inducing protective immunity against RSV infection
WO2018210871A1
(en)
2017-05-17
2018-11-22
Janssen Vaccines & Prevention B.V.
Methods and compositions for inducing protective immunity against rsv infection
EA202090049A1
(en)
2017-06-15
2020-04-15
Янссен Вэксинс Энд Превеншн Б.В.
POXVIRUS VECTORS CODING HIV ANTIGENES AND WAYS OF THEIR APPLICATION
JOP20190269A1
(en)
2017-06-15
2019-11-20
Voyager Therapeutics Inc
Aadc polynucleotides for the treatment of parkinson’s disease
EP3654860A1
(en)
2017-07-17
2020-05-27
Voyager Therapeutics, Inc.
Trajectory array guide system
CA3071011A1
(en)
2017-07-28
2019-01-31
Janssen Vaccines & Prevention B.V.
Methods and compositions for heterologous reprna immunizations
JP7221275B2
(en)
2017-08-03
2023-02-13
ボイジャー セラピューティクス インコーポレイテッド
Compositions and methods for delivering AAV
AU2018333566A1
(en)
2017-09-15
2020-02-27
Janssen Vaccines & Prevention B.V.
Method for the safe induction of immunity against RSV
EP3697905A1
(en)
2017-10-16
2020-08-26
Voyager Therapeutics, Inc.
Treatment of amyotrophic lateral sclerosis (als)
EA202090700A1
(en)
*
2017-10-16
2020-10-21
Глаксосмитклайн Байолоджикалс Са
REPLICATION-COMPETENT ADENOVIRAL VECTORS
US10864263B2
(en)
2017-11-20
2020-12-15
Janssen Pharmaceuticals, Inc.
Method of providing safe administration of adenoviral vectors encoding a zika virus antigen
EP3727446A1
(en)
2017-12-19
2020-10-28
Janssen Sciences Ireland Unlimited Company
Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
SG11202005451SA
(en)
2017-12-20
2020-07-29
Glaxosmithkline Biologicals Sa
Epstein-barr virus antigen constructs
BR112020013679A2
(en)
2018-01-04
2020-12-01
Iconic Therapeutics, Inc.
antitecid factor antibodies, antibody-drug conjugates and related methods
WO2019239311A1
(en)
2018-06-12
2019-12-19
Glaxosmithkline Biologicals Sa
Adenovirus polynucleotides and polypeptides
US20210301305A1
(en)
2018-06-13
2021-09-30
Voyager Therapeutics, Inc.
Engineered untranslated regions (utr) for aav production
US11713469B2
(en)
2018-07-20
2023-08-01
Janssen Vaccines & Prevention B.V.
Recombinant adenoviral vector expressing Zika antigen with improved productivity
MX2021000810A
(en)
2018-07-24
2021-04-28
Voyager Therapeutics Inc
Systems and methods for producing gene therapy formulations.
EP3861113A1
(en)
2018-10-04
2021-08-11
Voyager Therapeutics, Inc.
Methods for measuring the titer and potency of viral vector particles
WO2020072844A1
(en)
2018-10-05
2020-04-09
Voyager Therapeutics, Inc.
Engineered nucleic acid constructs encoding aav production proteins
TW202028468A
(en)
2018-10-15
2020-08-01
美商航海家醫療公司
Expression vectors for large-scale production of raav in the baculovirus/sf9 system
AU2020282369A1
(en)
2019-05-30
2022-01-20
Gritstone Bio, Inc.
Modified adenoviruses
TW202204380A
(en)
2020-01-31
2022-02-01
美商詹森藥物公司
Compositions and methods for preventing and treating coronavirus infection – sars-cov-2 vaccines
AU2021357520A1
(en)
2020-03-05
2022-09-29
Neotx Therapeutics Ltd.
Methods and compositions for treating cancer with immune cells
BR112022022937A2
(en)
2020-05-11
2022-12-20
Janssen Pharmaceuticals Inc
CORONAVIRUS PEAK PROTEIN STABILIZED FUSION PROTEINS
BR112022026408A2
(en)
2020-06-29
2023-01-17
Janssen Vaccines & Prevention Bv
VACCINE COMBINATION AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTION
AU2021303722A1
(en)
2020-07-06
2022-12-15
Janssen Pharmaceuticals, Inc.
Stabilized Corona virus spike protein fusion proteins
AU2021303478A1
(en)
2020-07-08
2023-02-16
Janssen Sciences Ireland Unlimited Company
RNA replicon vaccines against HBV
KR20230046313A
(en)
2020-08-06
2023-04-05
그릿스톤 바이오, 인코포레이티드
Multi-epitope vaccine cassette
KR20230147156A
(en)
2021-02-19
2023-10-20
얀센 백신스 앤드 프리벤션 비.브이.
Stabilized pre-fusion RSV FB antigen
WO2022175479A1
(en)
2021-02-19
2022-08-25
Janssen Vaccines & Prevention B.V.
Vaccine combinations against respiratory syncytial virus strain a and b infections
AU2022249741A1
(en)
2021-04-01
2023-09-21
Janssen Vaccines & Prevention B.V.
Stabilized pre-fusion piv3 f proteins
WO2023020939A1
(en)
2021-08-17
2023-02-23
Janssen Pharmaceuticals, Inc.
Sars-cov-2 vaccines
WO2023026182A1
(en)
2021-08-24
2023-03-02
Janssen Pharmaceuticals, Inc.
Sars-cov-2 vaccines
WO2023047348A1
(en)
2021-09-24
2023-03-30
Janssen Pharmaceuticals, Inc.
Stabilized corona virus spike protein fusion proteins
WO2023047349A1
(en)
2021-09-24
2023-03-30
Janssen Pharmaceuticals, Inc.
Stabilized coronavirus spike protein fusion proteins
WO2023111725A1
(en)
2021-12-14
2023-06-22
Janssen Pharmaceuticals, Inc.
Sars-cov-2 vaccines
WO2023110618A1
(en)
2021-12-16
2023-06-22
Janssen Vaccines & Prevention B.V.
Stabilized pre-fusion hmpv fusion proteins
WO2023198815A1
(en)
2022-04-14
2023-10-19
Janssen Vaccines & Prevention B.V.
Sequential administration of adenoviruses
Family Cites Families (8)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
ZA858044B
(en)
*
1984-11-01
1987-05-27
American Home Prod
Oral vaccines
FR2705361B1
(en)
*
1993-05-18
1995-08-04
Centre Nat Rech Scient
Viral vectors and use in gene therapy.
ATE399873T1
(en)
*
1993-07-13
2008-07-15
Centelion
DEFECTIVE ADENOVIRUS VECTORS AND THEIR USE IN GENE THERAPY
US5543328A
(en)
*
1993-08-13
1996-08-06
Genetic Therapy, Inc.
Adenoviruses having modified fiber proteins
US5820868A
(en)
*
1993-12-09
1998-10-13
Veterinary Infectious Disease Organization
Recombinant protein production in bovine adenovirus expression vector system
FR2716893B1
(en)
*
1994-03-03
1996-04-12
Rhone Poulenc Rorer Sa
Recombinant viruses, their preparation and their therapeutic use.
FR2725726B1
(en)
*
1994-10-17
1997-01-03
Centre Nat Rech Scient
VIRAL VECTORS AND USE IN GENE THERAPY
FR2726285B1
(en)
*
1994-10-28
1996-11-29
Centre Nat Rech Scient
ADENOVIRUSES CONTAINING VIABLE CONTAMINANT PARTICLES, PREPARATION AND USE
1997
1997-09-04
WO
PCT/US1997/015694
patent/WO1998010087A1/en
active
Application Filing
1997-09-04
US
US08/923,137
patent/US6083716A/en
not_active
Expired – Lifetime
1997-09-04
AU
AU42553/97A
patent/AU4255397A/en
not_active
Abandoned
Also Published As
Publication number
Publication date
US6083716A
(en)
2000-07-04
WO1998010087A1
(en)
1998-03-12
Similar Documents
Publication
Publication Date
Title
AU4255397A
(en)
1998-03-26
Chimpanzee adenovirus vectors
AU690054B2
(en)
1998-04-09
Earmuff-eyeglass combination
AU4040197A
(en)
1998-02-09
Microturbomachinery
AU3387997A
(en)
1998-01-07
Autonotification
AU2845197A
(en)
1998-01-15
Cycloalkano-pyridines
AU2784397A
(en)
1997-12-05
Contrast agents
AU4945197A
(en)
1998-05-11
Aminothiophenecarboxamides
AU4013397A
(en)
1998-03-06
Arylalkanoylpyridazines
AU4176997A
(en)
1998-04-02
3-alkyl-3-phenyl-piperidines
AU2684197A
(en)
1998-01-15
Handleset
AU4218597A
(en)
1998-04-24
Superseat
AU3701397A
(en)
1998-02-20
Anti-herpesviral agent
AU5854998A
(en)
1998-07-03
Microbicidal mixtures
AU2090897A
(en)
1997-09-16
Hydroxyhexahydropyridazines
AU3130597A
(en)
1997-12-05
Tristetraprolin
AU3942697A
(en)
1998-03-06
Hinged case
AU4332497A
(en)
1998-04-02
Endo-beta-galactosidase
AU2237197A
(en)
1997-09-10
Fishing-lure
AU1900097A
(en)
1997-11-06
Cremators
AU2145300A
(en)
2000-06-05
Adenoviral vectors
AU5002897A
(en)
1998-05-29
Gripper-accumulator
AU1597197A
(en)
1997-08-22
Thienoquinolines
AU3557397A
(en)
1998-02-25
Double-tau-profile
AU1643797A
(en)
1997-09-25
Repeater-system
AU3048097A
(en)
1998-01-05
Medium-conveying member
None